As a revolutionary solution to mRNA capping for vaccine and therapeutic production, CleanCap technology offers many advantages over traditional enzymatic capping:
Used in global commercial manufacturing programs, including a leading COVID-19 vaccine, CleanCap technology has proven to be the optimal mRNA vaccine capping method. See how we ramped up production to meet unprecedented demands in the global pandemic. View case study >
See how the evolution of cap analogs led to the creation of CleanCap technology and the enablement of a single,
co-transcriptional in vitro transcription reaction for manufacturing mRNA.
CleanCap technology is the fastest and easiest way to produce a 5’ Cap 1 mRNA structure with 95% efficiency. The “one-pot” solution requires fewer steps and less equipment than enzymatic capping—allowing for:
Quicker Process
Greater Production Potential
Better Return
CleanCap reagents are advancing some of the most cutting-edge pharmaceuticals and biotechnologies on the market today. Recognized as the superior capping method, CleanCap analogs are the future of mRNA therapeutic production.
From research use to GMP grade, CleanCap technology is available in a variety of formats to meet your unique production needs:
Ready to elevate your mRNA therapeutic development process?
Talk to our team about what may be the best option for you. Fill out the form below to get started.
